Naim Nazef

Company: Denali Therapeutics Inc.

Job title: Vice President, Oligonucleotide Chemistry

Seminars:

1:00 pm Workshop D: Refining the Next Antibody- Oligonucleotide Conjugates (AOC) & Delivery Chemistries 1:00 pm

Antibody-oligonucleotide conjugates (AOCs) represent a cutting-edge approach to improving targeted RNA therapeutics, offering enhanced precision in delivery, while overcoming key barriers such as biodistribution and cellular uptake. This workshop will focus on the latest advancements in AOC design, with a particular emphasis on brain shuttle strategies and delivery chemistry to optimize therapeutic outcomes for neurological…Read more

day: Pre-Conference Workshop Day - Track B P2

Panel Discussion: The Future of Oligonucleotide Therapeutics: Where Will the Field Be in 5 Years? 3:30 pm

How will advances in conjugation strategies, nanoparticle formulations, and tissue-specific targeting improve oligonucleotide biodistribution and efficacy? Beyond ALS, Huntington’s Disease & Alzheimer’s. What new indications, such as neurogenetic, epilepsies, neurodevelopmental and neuropsychiatric, are emerging for oligonucleotide-based therapies? What hurdles remain in scaling oligonucleotide production, and how will evolving regulatory frameworks shape the clinical and commercial…Read more

day: Day 2